Even as some companies have announced plans to postpone roadshows or meet investors on account of the novel coronavirus outbreak, banks still expect a robust IPO pipeline for Asia in the immediate future.
While the market grapples with the full impact of the Wuhan coronavirus, long-term investors typically follow Beijing’s policy playbook when deploying their capital. And if they don't, they probably should.
In partnership with China Investment Corporation (CIC) and BNP Paribas, Eurazeo’s China head tells FinanceAsia how France's largest private equity company plans to spend up to Eur1.5 billion to break into the world’s second largest economy.
After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.
Delisting stock and privatising is a big undertaking, but Chinese companies are increasingly using this method to both restructure and recapitalise their businesses. With the right financial partner, it can be a great opportunity to revitalise your brand.
Alibaba’s successful HK listing, combined with mounting pressure from PE investors, is forcing Chinese companies to consider listing in 2020 despite the woeful stock market performance of many who floated in 2019.